Prior authorization has long been a source of friction for providers and patients alike. In this interview, Dr. Michelle Gourdine, Chief Medical Officer at CVS Caremark, explains how the organization is deploying new processes and leveraging technology to simplify the prior authorization process for medications. These innovations make it faster for members and providers while continuing to uphold rigorous clinical integrity and quality.
The impact is measurable. In 2025 alone, Caremark processed 16.4 million prior authorization requests and proactively renewed 1.8 million approvals to prevent treatment gaps. Median processing times dropped from hours to just 34 minutes, with some approvals completed in seconds. For patients, that speed translates directly into faster access to therapies and better health outcomes.
Technology plays a critical role—but not without guardrails. Dr. Gourdine outlines how artificial intelligence is used to assist, not replace, clinical decision-making. From touchless prior authorization for select specialty drugs to ongoing review of clinical evidence, CVS Caremark’s approach balances faster access with safety, affordability and responsible use of powerful therapies. The result is a model designed to support providers, protect patients and sustain comprehensive prescription coverage.
How CVS Caremark is using innovative technology to simplify the prior authorization process
The editorial staff had no role in this post's creation.